ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för brivanib alaninate. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

24 träffar

Bibliografisk träff 2019-03-01

Treatment with Brivanib alaninate as a second-line monotherapy after Sorafenib failure in hepatocellular carcinoma: A case report.

Zhu H, Zhang C, Yang X, Yi C.

Medicine (Baltimore) · journal article; case reports; case-report · DOI 10.1097/md.0000000000014823

Bibliografisk träff 2016-10-19

Application of In-line Focused Beam Reflectance Measurement to Brivanib Alaninate Wet Granulation Process to Enable Scale-up and Attribute-based Monitoring and Control Strategies.

Narang AS, Stevens T, Macias K, Paruchuri S, Gao Z, Badawy S.

J Pharm Sci · journal article · DOI 10.1016/j.xphs.2016.08.025

Bibliografisk träff 2016-01-13

Integrated Application of Quality-by-Design Principles to Drug Product Development: A Case Study of Brivanib Alaninate Film-Coated Tablets.

Badawy SI, Narang AS, LaMarche KR, Subramanian GA, Varia SA, Lin J, Stevens T, Shah PA.

J Pharm Sci · journal article · DOI 10.1016/j.xphs.2015.11.023

Bibliografisk träff 2015-02-28

Role of Self-Association and Supersaturation in Oral Absorption of a Poorly Soluble Weakly Basic Drug.

Narang AS, Badawy S, Ye Q, Patel D, Vincent M, Raghavan K, Huang Y, Yamniuk A, Vig B, Crison J, Derbin G, Xu Y, Ramirez A, Galella M, Rinaldi FA.

Pharm Res · journal article · DOI 10.1007/s11095-015-1645-y

Bibliografisk träff 2014-12-02

Real-time assessment of granule densification in high shear wet granulation and application to scale-up of a placebo and a brivanib alaninate formulation.

Narang AS, Sheverev VA, Stepaniuk V, Badawy S, Stevens T, Macias K, Wolf A, Pandey P, Bindra D, Varia S.

J Pharm Sci · journal article · DOI 10.1002/jps.24233

Bibliografisk träff 2014-05-01

Beneficial effects of dual vascular endothelial growth factor receptor/fibroblast growth factor receptor inhibitor brivanib alaninate in cirrhotic portal hypertensive rats.

Lin HC, Huang YT, Yang YY, Lee PC, Hwang LH, Lee WP, Kuo YJ, Lee KC, Hsieh YC, Liu RS.

J Gastroenterol Hepatol · research support, non-u.s. gov't; journal article · DOI 10.1111/jgh.12480

Bibliografisk träff 2014-04-26

Quality by design development of brivanib alaninate tablets: degradant and moisture control strategy.

Badawy SI, Lin J, Gokhale M, Desai S, Nesarikar VV, LaMarche KR, Subramanian GA, Narang AS.

Int J Pharm · journal article · DOI 10.1016/j.ijpharm.2014.04.059

Bibliografisk träff 2013-05-20

Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carcinoma: the NCIC Clinical Trials Group and AGITG CO.20 Trial.

Siu LL, Shapiro JD, Jonker DJ, Karapetis CS, Zalcberg JR, Simes J, Couture F, Moore MJ, Price TJ, Siddiqui J, Nott LM, Charpentier D, Liauw W, Sawyer MB, Jefford M, Magoski NM, Haydon A, Walters I, Ringash J, Tu D, O'Callaghan CJ.

J Clin Oncol · clinical trial, phase iii; multicenter study; randomized controlled trial; journal article · DOI 10.1200/jco.2012.46.0543

Bibliografisk träff 2012-09-14

Metabolic chiral inversion of brivanib and its relevance to safety and pharmacology.

Gong J, Gan J, Masson E, Syed S, Xia YQ, Williams D, Pursley J, Jemal M, Humphreys WG, Iyer RA.

Drug Metab Dispos · journal article · DOI 10.1124/dmd.112.047340

Bibliografisk träff 2012-09-01

Brivanib: a review of development.

Chou T, Finn RS.

Future Oncol · review; journal article · DOI 10.2217/fon.12.104

Bibliografisk träff 2011-12-21

Acid-catalyzed hydrolysis of BMS-582664: degradation product identification and mechanism elucidation.

Zhao F, Derbin G, Miller S, Badawy S, Hussain M.

J Pharm Sci · journal article · DOI 10.1002/jps.23028

Bibliografisk träff 2011-06-09

Lack of effect of brivanib on the pharmacokinetics of midazolam, a CYP3A4 substrate, administered intravenously and orally in healthy participants.

Syed S, Clemens PL, Lathers D, Kollia G, Dhar A, Walters I, Masson E.

J Clin Pharmacol · clinical trial; research support, non-u.s. gov't; journal article · DOI 10.1177/0091270011407495

Bibliografisk träff 2011-05-31

Phase I dose-escalation study to determine the safety, pharmacokinetics and pharmacodynamics of brivanib alaninate in combination with full-dose cetuximab in patients with advanced gastrointestinal malignancies who have failed prior therapy.

Garrett CR, Siu LL, El-Khoueiry A, Buter J, Rocha-Lima CM, Marshall J, LoRusso P, Major P, Chemidlin J, Mokliatchouk O, Velasquez L, Hayes W, Feltquate D, Syed S, Ford S, Kollia G, Galbraith S, Nuyten DS.

Br J Cancer · research-article; clinical trial, phase i; journal article · DOI 10.1038/bjc.2011.182

Bibliografisk träff 2011-03-11

Brivanib alaninate for cancer.

Diaz-Padilla I, Siu LL.

Expert Opin Investig Drugs · research support, non-u.s. gov't; review; journal article · DOI 10.1517/13543784.2011.565329

Bibliografisk träff 2011-02-02

Metabolism and disposition of [14C]brivanib alaninate after oral administration to rats, monkeys, and humans.

Gong J, Gan J, Caceres-Cortes J, Christopher LJ, Arora V, Masson E, Williams D, Pursley J, Allentoff A, Lago M, Tran SB, Iyer RA.

Drug Metab Dispos · journal article · DOI 10.1124/dmd.110.037341

Bibliografisk träff 2010-11-01

Brivanib, a novel dual VEGF-R2/bFGF-R inhibitor.

Dempke WC, Zippel R.

Anticancer Res · review; journal article

Bibliografisk träff 2010-03-18

Experimental treatment of oestrogen receptor (ER) positive breast cancer with tamoxifen and brivanib alaninate, a VEGFR-2/FGFR-1 kinase inhibitor: a potential clinical application of angiogenesis inhibitors.

Patel RR, Sengupta S, Kim HR, Klein-Szanto AJ, Pyle JR, Zhu F, Li T, Ross EA, Oseni S, Fargnoli J, Jordan VC.

Eur J Cancer · research support, non-u.s. gov't; research-article; research support, u.s. gov't, non-p.h.s.; journal article; research support, n.i.h., extramural · DOI 10.1016/j.ejca.2010.02.018

Bibliografisk träff 2009-12-19

Amplification of fibroblast growth factor receptor-1 in breast cancer and the effects of brivanib alaninate.

Shiang CY, Qi Y, Wang B, Lazar V, Wang J, Fraser Symmans W, Hortobagyi GN, Andre F, Pusztai L.

Breast Cancer Res Treat · research support, non-u.s. gov't; journal article · DOI 10.1007/s10549-009-0677-6

Bibliografisk träff 2009-04-26

Preclinical pharmacokinetics and in vitro metabolism of brivanib (BMS-540215), a potent VEGFR2 inhibitor and its alanine ester prodrug brivanib alaninate.

Marathe PH, Kamath AV, Zhang Y, D'Arienzo C, Bhide R, Fargnoli J.

Cancer Chemother Pharmacol · journal article · DOI 10.1007/s00280-009-1002-0

Bibliografisk träff 2008-11-01

Direct and indirect separations of five isomers of Brivanib Alaninate using chiral high-performance liquid chromatography.

He BL, Shi Y, Kleintop B, Raglione T.

J Chromatogr B Analyt Technol Biomed Life Sci · comparative study; journal article · DOI 10.1016/j.jchromb.2008.08.022

Bibliografisk träff 2008-10-01

Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma.

Huynh H, Ngo VC, Fargnoli J, Ayers M, Soo KC, Koong HN, Thng CH, Ong HS, Chung A, Chow P, Pollock P, Byron S, Tran E.

Clin Cancer Res · research support, non-u.s. gov't; journal article · DOI 10.1158/1078-0432.ccr-08-0509

Bibliografisk träff 2008-02-21

Discovery of brivanib alaninate ((S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor (BMS-540215).

Cai ZW, Zhang Y, Borzilleri RM, Qian L, Barbosa S, Wei D, Zheng X, Wu L, Fan J, Shi Z, Wautlet BS, Mortillo S, Jeyaseelan R, Kukral DW, Kamath A, Marathe P, D'Arienzo C, Derbin G, Barrish JC, Robl JA, Hunt JT, Lombardo LJ, Fargnoli J, Bhide RS.

J Med Chem · journal article · DOI 10.1021/jm7013309

Bibliografisk träff 2007-07-01

Discovery and validation of biomarkers that respond to treatment with brivanib alaninate, a small-molecule VEGFR-2/FGFR-1 antagonist.

Ayers M, Fargnoli J, Lewin A, Wu Q, Platero JS.

Cancer Res · journal article · DOI 10.1158/0008-5472.can-06-4555

Bibliografisk träff 2006-04-01

Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5- methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan- 2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor.

Bhide RS, Cai ZW, Zhang YZ, Qian L, Wei D, Barbosa S, Lombardo LJ, Borzilleri RM, Zheng X, Wu LI, Barrish JC, Kim SH, Leavitt K, Mathur A, Leith L, Chao S, Wautlet B, Mortillo S, Jeyaseelan R, Kukral D, Hunt JT, Kamath A, Fura A, Vyas V, Marathe P, D'Arienzo C, Derbin G, Fargnoli J.

J Med Chem · journal article · DOI 10.1021/jm051106d